|Day Low/High||159.04 / 161.19|
|52 Wk Low/High||114.27 / 197.00|
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
The Fed chairman's news conference threw markets for a loop with hawkish words that did not support the Fed's dovish actions.
Here are my five rules for handling earnings season.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
Stocks see a nice surge on the open on optimism around trade talks resuming between the U.S. and China, although negotiations will be ongoing for many months and no permanent resolution seems on the horizon. The U.S. PMI Manufacturing Index also cam...
It is good to be sitting in for Doug Kass here on The Daily Diary as we open trading in the second half of 2019. June ended on an up note as all the major indices drifted up last week to close out the month and quarter. The market did an admirable j...
Watch the Russell 2000, housing activity, and mergers and acquisitions.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
With no other bidder expected to emerge, this is a high risk arbitrage play.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Let's look closer at the charts and indicators of ABBV.
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
South Korea is the plastic surgery capital of the world. These companies are manufacturing botox strains - but the big business is abroad, if they can crack the China and U.S. markets.
These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.
Shares of the maker of Botox are struggling despite its latest results exceeding expectations.
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
In this day and age, companies must be 'disruptors' or get left in the dust.
With shares breaking above the recent, albeit small, pennant, there might be reason for optimism.